2016 循证共识声明:急性重症溃疡性结肠炎

2016-06-01 国外消化科相关专家小组(统称) Aliment Pharmacol Ther. 2016 Jul;44(2):127-44.

急性重症溃疡性结肠炎是溃疡性结肠炎的一种潜在威胁生命的并发症,本文主要针对急性重症溃疡性结肠炎的定义,治疗目标,实验室检查,内镜检查,临床路径,持续评估,多学科管理,营养治疗,深静脉血栓的预防,糖皮质激素的应用等内容共提出了32条共识声明。

中文标题:

2016 循证共识声明:急性重症溃疡性结肠炎

英文标题:

acute severe ulcerative colitis - evidence-based consensus statements.

发布日期:

2016-06-01

简要介绍:

急性重症溃疡性结肠炎是溃疡性结肠炎的一种潜在威胁生命的并发症,本文主要针对急性重症溃疡性结肠炎的定义,治疗目标,实验室检查,内镜检查,临床路径,持续评估,多学科管理,营养治疗,深静脉血栓的预防,糖皮质激素的应用等内容共提出了32条共识声明。

拓展指南:溃疡性结肠炎相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2016 循证共识声明:急性重症溃疡性结肠炎)] GetToolGuiderByIdResponse(projectId=1, id=b226d1c0013a93f9, title=2016 循证共识声明:急性重症溃疡性结肠炎, enTitle=acute severe ulcerative colitis - evidence-based consensus statements., guiderFrom=Aliment Pharmacol Ther. 2016 Jul;44(2):127-44., authorId=null, author=, summary=急性重症溃疡性结肠炎是溃疡性结肠炎的一种潜在威胁生命的并发症,本文主要针对急性重症溃疡性结肠炎的定义,治疗目标,实验室检查,内镜检查,临床路径,持续评估,多学科管理,营养治疗,深静脉血栓的预防,糖皮质激素的应用等内容共提出了32条共识声明。, cover=, journalId=null, articlesId=null, associationId=950, associationName=国外消化科相关专家小组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Wed Jun 01 00:00:00 CST 2016, originalUrl=, linkOutUrl=, content=急性重症溃疡性结肠炎是溃疡性结肠炎的一种潜在威胁生命的并发症,本文主要针对急性重症溃疡性结肠炎的定义,治疗目标,实验室检查,内镜检查,临床路径,持续评估,多学科管理,营养治疗,深静脉血栓的预防,糖皮质激素的应用等内容共提出了32条共识声明。<br> <br> 拓展指南:<strong>与<font color=red>溃疡性结肠炎</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=b226d1c0013a93f9" title="2016 循证共识声明:急性重症溃疡性结肠炎" target=_blank>2016 循证共识声明:急性重症溃疡性结肠炎</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=de6e01c001151290" title="2015 多伦多共识:非住院性溃疡性结肠炎的医学管理指南" target=_blank>2015 多伦多共识:非住院性溃疡性结肠炎的医学管理指南</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=ffa341c0011a5147" title="2015 NICE技术评估指导:应用英夫利昔单抗,阿达木单抗和戈利木单抗治疗应用传统疗法失败的中至重度活动性溃疡性结肠炎(TA329)" target=_blank>2015 NICE技术评估指导:应用英夫利昔单抗,阿达木单抗和戈利木单抗治疗应用传统疗法失败的中至重度活动性溃疡性结肠炎(TA329)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=3483a1c0010a56ac" title="2014 ASCRS实践参数:溃疡性结肠炎的手术治疗" target=_blank>2014 ASCRS实践参数:溃疡性结肠炎的手术治疗</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=225791c000995011" title="2013 NICE CG166 儿童、青少年、成人溃疡性结肠炎的管理" target=_blank>2013 NICE CG166 儿童、青少年、成人溃疡性结肠炎的管理</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E6%BA%83%E7%96%A1%E6%80%A7%E7%BB%93%E8%82%A0%E7%82%8E" target=_blank>有关溃疡性结肠炎更多指南</a></ul>, tagList=[TagDto(tagId=69964, tagName=急性重症溃疡性结肠炎)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3147, appHits=356, showAppHits=0, pcHits=2138, showPcHits=1098, likes=143, shares=6, comments=2, approvalStatus=1, publishedTime=Sun Jan 22 10:23:16 CST 2017, publishedTimeString=2016-06-01, pcVisible=1, appVisible=1, editorId=5295957, editor=lili, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=lili, createdTime=Sun Jan 22 10:23:16 CST 2017, updatedBy=null, updatedName=null, updatedTime=Thu Jan 04 22:29:26 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2016 循证共识声明:急性重症溃疡性结肠炎)])
2016 循证共识声明:急性重症溃疡性结肠炎
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=172265, encodeId=8be01e22658f, content=国内的什么时候有啊,这些临床意义很大, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2012638, createdName=1e1f3761m34(暂无匿称), createdTime=Tue Jan 24 07:04:25 CST 2017, time=2017-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172261, encodeId=44c01e226150, content=好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2012638, createdName=1e1f3761m34(暂无匿称), createdTime=Tue Jan 24 07:03:37 CST 2017, time=2017-01-24, status=1, ipAttribution=)]
    2017-01-24 1e1f3761m34(暂无匿称)

    国内的什么时候有啊,这些临床意义很大

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=172265, encodeId=8be01e22658f, content=国内的什么时候有啊,这些临床意义很大, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2012638, createdName=1e1f3761m34(暂无匿称), createdTime=Tue Jan 24 07:04:25 CST 2017, time=2017-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=172261, encodeId=44c01e226150, content=好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ede2012638, createdName=1e1f3761m34(暂无匿称), createdTime=Tue Jan 24 07:03:37 CST 2017, time=2017-01-24, status=1, ipAttribution=)]
    2017-01-24 1e1f3761m34(暂无匿称)

    好东西

    0